4D Molecular Therapeutics (FDMT)

• Market cap: $591M
• 1 day: -8.2%
• 5 days: -11.72%
• 1 month: 22.56%
• 3 months: 12.55%
• 6 months: 43.77%
• Year to date: 54.37%
• 1 year: 157.99%
• 5 years: -50.29%
• 10 years: -72.1%
• Sector: Healthcare
• Industry: Biotechnology

About: 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Employees: 196